Get 50% OFF This Summer!
Shalby
No Data Available
Investor Sentiment
Shalby Share price and Fundamental Analysis
Key Metrics
Included In
Stock Returns
CAGR
Revenue Growth
Net Profit Growth
Operating Profit Growth
Dividend Growth
Stock Returns CAGR
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
Shalby Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Shalby Limited is an Ahmedabad-headquartered chain of multi-specialty hospitals and has a pan-India presence. It predominantly operates through 11 hospitals with an aggregate bed capacity of 2,012 beds. Out of these, 4 are located in Ahmedabad and 1 each at Vapi, Surat, Indore, Jabalpur, Mohali, Jaipur and Mumbai. Besides this, Shalby has 40 Outpatient Clinics spread across 35 cities of India and 7 Shalby Arthroplasty Centre of Excellence (SACE). It is expanding its footprint in western and central India. Shalby's international footprint is spread across Africa, UAE, Bangladesh and Cambodia consisting of 6 outpatient clinics and 1 SACE in Africa, 2 SACE in the UAE and 1 outpatient clinic each in Bangladesh and Cambodia.
Shalby is one of the leading multi-specialty chain of hospitals in India. The Hospitals are tertiary care hospitals, few of which also offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations.
Led by Dr. Vikram Shah, an orthopaedic surgeon with more than 25 years of professional experience, The Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from a focus on orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL.
Shalby Ltd was originally incorporated as a private limited company with the name 'Shalby Hospital Private Limited' on August 30, 2004. Subsequently, The Company was converted to a public limited company and the name of the company was changed to 'Shalby Hospital Public Limited' on May 15, 2006. The name of the Company was subsequently changed to Shalby Hospitals Limited on July 26, 2006. In 2007, the company established and commenced operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad. The name of the Company was changed to Shalby Limited on February 13, 2008.
The company commenced a new hospital Shalby Vapi at Vapi in April 2012. The company commenced a new hospital Krishna Shalby in Ahmedabad in October 2012.
The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015.
In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali.
In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries.
On 22/05/2016 the company filed Draft Red Herring Prospectus and on 29/11/2017 filed Red Herring Prospectus with SEBI for raising Rs. 504.80 cr. The Issue dates were from 05/12/2017 to 07/12/2017 with Price Band of Rs. 245 to Rs. 248. The Issue got subscribed 2.27 times leading to its Issue Price being fixed at Rs. 248. The Shares got listed in BSE and NSE on 15/12/2017 at Rs. 237 which is 4.44% below Issue Price.On 27 March 2018, Shalby Limited announced that it has signed Memorandum of Understanding (MoU) to establish state- of- the art, Heart & Lung Transplant Centres, across all Shalby Units in India in association with Gleneagles Global Health City to provide comprehensive medical care facilities to patients across all Shalby units in India. This arrangement will facilitate patients and families residing in tier- II & tier-Ill cities and its catchment areas in a big way, by reducing their dependence on select metro cities for such life saving programs. This will enable Shalby and Gleneagles Global to expand their respective business verticals, adding more features, capabilities and boost patients footfalls.
Shalby Limited (Shalby Multispecialty Hospitals), Ahmedabad signed a Memorandum of Understanding (MOU) with Sen Sok International University Hospital, Phnom Penh, Cambodia on April 12, 2018. Under the aegis of this MOU, to begin with, Shalby will be sending Specialists to Sen Sok Hospital for Orthopedic Specialty, which may be expanded to other specialties on mutual agreement, from time to time. Further, under the scope of the MOU, Shalby Academy, a unit of Shalby Limited, will allow nursing and Paramedic staff from Sen Sok International University Hospital to undergo various academic courses being run by Shalby Academy in India. Shalby Academy has been conducting various courses covering Paramedics, Hospital Management and specialized programs for doctors to excel in their careers.
On 4 June 2018, Shalby Limited signed Memorandum of Understanding (MoU) with Berkeley Health Education P. Ltd, initiatives by promoter of Dabur Group, for conducting several programmes in Healthcare sector wherein Berkeley will organize the courses and Shalby will impart practical training at its various units across India. This Collaboration will benefit Nurses, Para Medical Staff and Doctors as several courses in different field of Healthcare will be conducted under this arrangement.
On 1 September 2018, Shalby Limited informed the stock exchanges that Shalby Hospitals, Indore Unit has received the approval for Renal Transplant for a period of 5 years with effect from 6 July 2018 and Shalby Indore has successfully carried out one Renal Transplant, recently. This approval to our facility will facilitate patients from Madhya Pradesh and nearby states to reduce their dependence on select Metro cities for such life saving programs.
On 20 September 2018, Shalby Hospitals, Jaipur performed a rare surgery on an 11 year old girl and removed an ovarian mass weighing 12.5 kg intact, to avoid spillage.
On 24 September 2018, Shalby Limited informed the stock exchanges that credit rating agency ICRA Limited has upgraded the long-term ratings to [ICRA] A (pronounced as ICRA A) from [ICRA A-] (pronounced as ICRA A minus) on the term loans and fund based facilities aggregating to Rs 103.02 crore availed by the company. ICRA has also revised its outlook on the long-term rating to 'Positive' from 'Stable'.
Shalby Share Price
Shalby share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Shalby Market Cap
Market capitalization of Shalby indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Shalby is valued compared to its competitors.
Shalby PE Ratio
Shalby PE ratio helps investors understand what is the market value of each stock compared to Shalby 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
Shalby PEG Ratio
The PEG ratio of Shalby evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Shalby ROE (Return on Equity)
Return on Equity (ROE) measures how effectively Shalby generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Shalby ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of Shalby in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Shalby Total Debt
Total debt of Shalby shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
Shalby Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of Shalby compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
Shalby CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of Shalby over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Shalby Technical Analysis
Technical analysis of Shalby helps investors get an insight into when they can enter or exit the stock. Key components of Shalby Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Shalby shares often struggle to rise above due to selling pressure.
Shalby Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Shalby ’s financial health and profitability.
Shalby Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Shalby Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
Shalby Financials
The financials of Shalby provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
Shalby Profit and Loss Statements
The profit and loss statement of Shalby highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Shalby .
Shalby Balance Sheet
The balance sheet presents a snapshot of Shalby ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Shalby Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month